Cardiac effects of SGLT2 inhibitors: the sodium hypothesis.
about
Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission.Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis.Clinical and translational science in cardiovascular research: highlights from the American Heart Association Scientific Sessions 2017: Changing view on the concept of cardiovascular risk and blood pressure targets.Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts.The Role of Sodium in Diabetic Cardiomyopathy
P2860
Cardiac effects of SGLT2 inhibitors: the sodium hypothesis.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Cardiac effects of SGLT2 inhibitors: the sodium hypothesis.
@en
Cardiac effects of SGLT2 inhibitors: the sodium hypothesis.
@nl
type
label
Cardiac effects of SGLT2 inhibitors: the sodium hypothesis.
@en
Cardiac effects of SGLT2 inhibitors: the sodium hypothesis.
@nl
prefLabel
Cardiac effects of SGLT2 inhibitors: the sodium hypothesis.
@en
Cardiac effects of SGLT2 inhibitors: the sodium hypothesis.
@nl
P2860
P50
P356
P1476
Cardiac effects of SGLT2 inhibitors: the sodium hypothesis
@en
P2093
Christoph Maack
P2860
P356
10.1093/CVR/CVX149
P577
2018-01-01T00:00:00Z